Searchable abstracts of presentations at key conferences in endocrinology

ea0011p316 | Diabetes, metabolism and cardiovascular | ECE2006

Endothelial, inflammatory and endocrine markers in women with PCOS before and after metformin treatment

Heutling D , Schulz H , Nickel I , Kleinstein J , Kaltwasser P , Randeva HS , Krzyzanowska K , Mittermayer F , Wolzt M , Schernthaner G , Lehnert H

Polycystic ovary syndrome (PCOS) affects more than 5% of women in reproductive age and is characterized by a heterogeneous spectrum of oligoanovulation and biochemical or clinical evidence of hyperandrogenism. Insulin resistance and compensatory hyperinsulinaemia play a significant role in pathogenesis of PCOS.Chronic low level inflammation and an increased risk for cardiovascular disease and type2-diabetes are reported in women with PCOS.<p class="a...

ea0070aep596 | Pituitary and Neuroendocrinology | ECE2020

Efficacy and safety of long-acting pasireotide (LA-PAS) in patients with uncontrolled acromegaly: Results from the prospective cohort of european observational acronis study

Pivonello Rosario , Tabarin Antoine , Colao Annamaria , Kaltsas Gregory , Gonzalez-Molero Inmaculada , Neggers Sebastian , Venegas Moreno Eva , Kocjan Tomaz , Karges Wolfram , Krzyzanowska-Mittermayer Katarzyna , Heck Ansgar , Eden Engstrom Britt , Marques Ruben , O’Brien Eamonn , Manne Shobha , Vincenzi Beatrice , Schöfl Christof

Introduction: Results of the first European real-world evidence from retrospective cohort of ACRONIS study previously confirmed the efficacy and tolerability of LA-PAS in heavily pre-treated, uncontrolled acromegaly patients. Here, we report results of the second interim analysis reflecting the prospective cohort.Methods: Patients who were treated with LA-PAS for ≥6 months were included in this analysis. The primary objective was to document treatm...